moxetumomab pasudotox
Selected indexed studies
- Moxetumomab Pasudotox. (, 2006) [PMID:30371998]
- Moxetumomab Pasudotox. (, 2012) [PMID:31644208]
- Moxetumomab pasudotox for the treatment of hairy cell leukemia. (Expert Opin Biol Ther, 2019) [PMID:31045462]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Moxetumomab Pasudotox. (2006) pubmed
- Moxetumomab Pasudotox. (2012) pubmed
- Moxetumomab pasudotox for the treatment of hairy cell leukemia. (2019) pubmed
- Moxetumomab Pasudotox: Clinical Experience in Relapsed/Refractory Hairy Cell Leukemia. (2019) pubmed
- Moxetumomab Pasudotox: First Global Approval. (2018) pubmed
- Moxetumomab Pasudotox in Hairy Cell Leukaemia: A Profile of Its Use. (2021) pubmed
- Moxetumomab pasudotox for the treatment of relapsed and/or refractory hairy cell leukemia. (2019) pubmed
- Moxetumomab pasudotox for hairy cell leukemia: preclinical development to FDA approval. (2019) pubmed
- Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations. (2019) pubmed
- Moxetumomab pasudotox: A first-in-class treatment for hairy cell leukemia. (2019) pubmed